Judge Finds Company Did Not Mislead Investors About FDA Approval Prospects
NEW YORK — A federal judge in New York granted a biopharmaceutical company and its CEO’s motion to dismiss shareholders’ putative class action alleging the company and the CEO misled the...To view the full article, register now.
Already a subscriber? Click here to view full article